论文部分内容阅读
目的:观察重组干扰素α-2b栓联合保妇康栓治疗宫颈高危型乳头瘤(HPV)病毒亚临床感染的临床疗效。方法:选取宫颈高危型HPV亚临床感染患者70例,随机分为联合组和对照组,各35例。联合组予以重组人干扰素a-2b栓联合保妇康栓,非月经期内交替用药;对照组予以单纯重组人干扰素α-2b栓非月经期内用药治疗。2组疗程均为3月。评估2组患者治疗3月后的临床效果,并比较其高危型HPV清除率。结果:临床总有效率联合组94.29%,对照组77.14%,2组比较,差异有统计学意义(P<0.05)。HPV清除总有效率,联合组88.57%,对照组68.57%,2组比较,差异有统计学意义(P<0.05)。结论:重组干扰素α-2b栓联合保妇康栓治疗宫颈高危型HPV亚临床感染的疗效较确切,能更有效地清除HPV,提高临床效果。
Objective: To observe the clinical efficacy of recombinant interferon α-2b suppository combined with Baofukang suppository in the treatment of sub-clinical infection of cervical high-risk papillomavirus (HPV). Methods: Seventy patients with cervical high-risk HPV subclinical infection were randomly divided into combined group and control group, 35 cases each. The combination group was treated with recombinant human interferon alpha-2b suppository and Baofukang suppository during the non-menstrual period. The control group was treated with recombinant interferon alpha-2b only during non-menstrual period. The two groups were treated in March. The clinical efficacy of two groups of patients after 3 months of treatment was evaluated and their high-risk type of HPV clearance was compared. Results: The total clinical effective rate was 94.29% in the combined group and 77.14% in the control group. There was significant difference between the two groups (P <0.05). The total effective rate of HPV removal was 88.57% in the combined group and 68.57% in the control group. There was significant difference between the two groups (P <0.05). Conclusion: The effect of recombinant interferon α-2b suppository combined with Baofukang suppository in the treatment of subclinical cervical HPV infection is more accurate and effective in removing HPV and improving clinical efficacy.